What are the leading stocks in medical stocks?
Health concept stocks have 109 listed companies such as China Tai Insurance, Pharmacopeia, Aier Ophthalmology, Zhifei Biological, BOE A, Guotai Junan, Yunnan Baiyao, Fosun Pharmaceuticals, Tiger Pharmaceuticals, Kanglong Huacheng and so on. The following Xiao Biao brought medical beauty stocks what leading stocks, we take a look at it, I hope to bring reference.
What are the leading stocks in medical beauty stocks
1. Kainan Health: annual mid-year net profit forecast 80.73%, up 47.83% in the first half of 2021; the company's wholly-owned subsidiary, Kiyon America, is committed to innovation and development of cellular level skin repair technology, the core products used in the world's leading clinical-grade biological proteins Genetic recombination and independent patented protein compounding technology, effective in the field of anti-aging repair and beauty. The main reason for the change in the company's performance is that the downstream market of the product has been opened, no longer affected by the epidemic, the industry's boom index has gradually recovered. 2021, the company in the global market to seize all the business opportunities of the recovery of consumption, and the launch of a variety of new products as well as to improve the industrial chain so as to realize the performance of the sharp rise.
2. Aoyuan Meigu: annual mid-year net profit forecast 127.46%, 2021 first half rose 178.03%; the company's wholly-owned subsidiary Guangzhou Aomei and KD company *** with the formation of a joint venture, and by the joint venture company in the domestic agent products. kD was founded in South Korea, from the main business can be seen in his is a sales of medical cosmetic equipment, as well as cosmetic active raw materials in the development and research of high-tech companies. Development and research of high-tech companies. The reason for the surge in performance and the factors brought about by the consolidation of the second quarter of the acquisition of zhejiang liantianmei company. The first half of last year due to the impact of the epidemic, which led to the production and sales of chemical fiber segment has been affected to some extent.
3. Ha Sanlian: annual mid-year net profit forecast 1892.11%, up 251.58% in the first half of 2021; Ha Sanlian affixed to the medical beauty of the reason is to participate in the Shierjia, most of the company's main products for the medical beauty supplies, including: medical hyaluronic acid Na repair stickers, medical hyaluronic acid Na repair liquid. The company holds 100% of the equity of North Star Pharmaceutical foreign investment, half-yearly report of the reason for the increase is mainly from the non-recurring gains and losses, the company recognized investment income on the company's 2021 consolidated statement of level of profit and loss impact amounted to about 56,600,000 yuan.
4. Huaxi biological annual mid-year report net profit forecast 35.00%, 2021 first half rose 102.23%; the company as the authentic leader of the medical beauty industry, currently belongs to the core high-tech enterprises, but also the world's leading hyaluronic acid microbial fermentation producers, also the industrial scale also belongs to the forefront of the world, but also the first to realize the microbial fermentation method of hyaluronic acid production enterprises It is also one of the first companies to realize the production of hyaluronic acid by microbial fermentation. In June last year, the company also acquired 100% of the equity of Foset, and opened the leading domestic hyaluronic acid series of products production equipment. The company's half-yearly report increased mainly because of the raw materials business as well as medical terminal business growth, its skin care business in the first half of the year is all the way to the momentum of the song, for the company to bring nearly 100% revenue growth. At the same time, in the revenue growth period the company also increased efforts to give strong support to the underlying scientific and technological research and development.
5. Lanzi shares: annual mid-year net profit forecast 3228.26%, up 105.52% in the first half of 2021; domestic three major medical brand "Milan", "crystal skin", "high". A lifetime" are held by Lancel, in the international market has also invested in South Korea's well-known medical beauty group DMG. This year, in addition to accelerating the pace in the women's fashion industry chain, it has also been advancing in medical beauty, realizing sound business development, which is important for the company's profit.
6. Haohai Shengke: annual mid-year net profit forecast 753.70%, up 192.55% in the first half of 2021; the company specializes in the field in the dermal filler hyaluronic acid, from the upper reaches of raw materials to the terminal preparations of the whole industrial chain of research and development, production and sales capacity to two adapt to the current trend of the raw material production of the company. The company's performance changes mainly from the impact of the epidemic, the first half of this year, the epidemic has been effectively controlled, so as to carry out various marketing activities to expand the influence and increase product demand.
7. Specialty pharmaceuticals: annual mid-year net profit forecast 180.00%, 2021 first half rose 21.00%; the company intends to invest 100 million yuan to set up guangdong temei health science and technology industry limited company, to be set up for the Specialty Pharmaceutical Group's health industry investment and operation platform, its development direction includes full layout of the development of the field of medical and beauty services and investment. The company's core product sales gradually incremental, the business also returned to normal levels, the company company constantly strengthen brand building, optimize product structure, increase internal management, adhere to the cost reduction and efficiency, has achieved better results.
8. Jinfa Rabi: annual mid-year net profit forecast 114.72%, up 139.51% in the first half of 2021; the company has an older seniority in the medical beauty industry, and invested in medical beauty enterprise Guangdong Hanfei Hospital, in the company's subsidiary is also holding five medical beauty institutions. The company's business plan in an orderly manner, the online and offline channel layout, marketing strategy, management mode, product development mode adjustment, the company's income this year compared with the same period last year has a greater degree of recovery.
9. Chengzhi shares: annual mid-year net profit forecast 458.77%, up 24.54% in the first half of 2021; wholly owned subsidiary Chengzhi Life Science and Technology Co. official website shows that there is production of hyaluronic acid. Domestic supply and demand for medical beauty to last year after the epidemic has been significantly improved, clean energy business due to raw material price reversal, resulting in a substantial increase in sales of the company's related products, at the same time the company's company semiconductor liquid crystal display material market demand increased, production and sales volume increased significantly, also brought the company's profit increase.
10. Phaidon shares: annual mid-year net profit forecast 100.00%, up 35.71% in the first half of 2021; Haihua science and technology long-term attention to hyaluronic acid product production technology, and has been pilot production of related products. Shanghai Shaohua Biotechnology Development Co., Ltd, a subsidiary of Haihua Science and Technology, is mainly responsible for the company's future promotion and sales of medical products, as well as technological research and development. The company's chemical trading business to adjust the business ideas, focusing on core suppliers, core customers, core products, strengthen control, operating results increased significantly year-on-year.
What are the leading stocks in the health industry
Leading stocks 1, Lexin Medical: The company's business has the research and development and operation of intelligent health cloud platform.
Leading stocks 2, rongjie health: the company is engaged in far infrared health equipment research and development, production and sales.
Leading stock 3, Yuexin health: the company is mainly engaged in the health industry, architectural ceramics business, ecological health building materials business.
Health leading stocks of the recent situation
Leisure Heart Medical: leading stocks
In the last 5 days of Lexin Medical shares fell 4.04%, the total market value fell 83.7335 million, the current market value of 2.074 billion yuan. 2022 stock price fell -72.05%. December 21 news, Lexin Medical December 21 main fund net outflow of 1.4636 million yuan, large single net outflow of 1.4636 million yuan, retail fund net outflow of 1.3485 million yuan.
Rongjie Health: leading stocks
In the last five trading days, the stock price fell 7.77%, the highest price of $4.11, the total market value fell by 233 million.December 21 news, Rongjie Health main net inflow of 4,510,300 yuan, large single net inflow of 1,119,000 yuan, retail net outflow of 1,831,800 yuan.
Rongjie Health: leading stocks
In the last five trading days, the stock price rose 7.74%, the highest price of 5.39 yuan, the total market value rose 361 million, the current market value of 4.67 billion yuan. Funds flow data, on December 21, the main funds net outflow of 950,915,000 yuan, super-large single net outflow of 780,502,000 yuan, large single net outflow of 17,041,300 yuan, retail funds net inflow of 71,777,000 yuan.
Lexin Medical (300562)
The financial report shows that in the third quarter of 2022, the company's operating income of 299 million yuan; net profit attributable to listed shareholders of 2,054,900 yuan; fully diluted return on net assets of 0.19%; gross profit margin of 23.24%, earnings per share of 0.01 yuan.
Rongjie Health (300247)
Rongjie Health released its Q3 2022 financial results, realizing operating income of 94.5235 million yuan, up -4.88% year-on-year, and net income of 3.7131 million yuan, -82.7% year-on-year.
Yuexin Health (002162)
The financial report shows that in the third quarter of 2022, the company's operating income of 350 million yuan; net profit attributable to listed shareholders of -76,945,000 yuan; fully diluted return on net assets of -6.22%; gross profit margin of 20.6%, earnings per share -0.08 yuan.
Health-related stocks what else
1, Annaier (002875): the company is mainly engaged in high-end children's clothing business. December 21, Annaier opening quote 23.2 yuan, closed at 25.380 yuan, up 10.01%. The day's highest price of 25.38 yuan, the lowest reached 22.51 yuan, the volume of 28.224 million lots, the total market value of 5.397 billion yuan.
2, Guolian aquatic (300094): the company's main business for shrimp and tilapia seedlings, aquatic feed, primary processing products and deep-processed food. Southern wealth network on December 21, Guolian aquatic shares rose 6.07%, as of the closing price of 6.470 yuan, market value of 7.334 billion yuan. Intraday stock price peak price of 6.68 yuan, as low as 6.1 yuan, turnover 145 million lots.
3, Hai Zheng Pharmaceutical (600267): the company is mainly engaged in the research and development of APIs, preparations, production and sales. Southern wealth network on December 21, Hai Zheng Pharmaceutical shares rose 4%, as of the closing price of 11.190 yuan, market value of 13.408 billion yuan. The highest price of the stock price of 11.69 yuan, the lowest reached 10.82 yuan, the volume of 28,231,500 lots.
4, shuhua sports (605299): the company is mainly engaged in fitness equipment and display rack products research and development, production and sales.December 21 evening resumption of news, shuhua sports latest reported 11.170 yuan, up 2.95%. Volume of 9,151,900 lots, total market capitalization of 4.596 billion yuan.
5, nine Ann medical (002432): the company's business has the research and development, production and sales of home medical equipment. Beijing time on December 21, nine Ann medical opening quote 59.24 yuan, closed at 60.820 yuan, compared with the previous trading day's close up 2.65% at 59.25 yuan. The day's highest price of 61.56 yuan, the lowest reached 58.88 yuan, with a turnover of 28.177 million lots, a total market capitalization of 29.45 billion yuan.
6, Xi Wang Foods (000639): the company's main business is Xi Wang brand series of healthy edible oil. December 21, Xi Wang Foods evening resumption of the news, the stock price fell 0.41% in 7 days, this year's gains fell -6.12%, the latest at 4.900 yuan, up 2.3%, the market value of 5.289 billion yuan.
7, light media (300251): the company is engaged in the film business. December 21 evening resumption of news, light media 5 days within the share price fell 4.36%, this year's gain fell -56.61%, the latest reported 8.250 yuan, turnover 120 million yuan.
8, Kexing Pharmaceuticals (688136): the company is engaged in the research and development, production and sales of biological drugs business. December 21 news, Kexing Pharmaceuticals opened at 24.21 yuan, closed at 24.800 yuan, up 2.44%. The day's highest price of 25.36 yuan, the lowest reached 24.1 yuan, the total market value of 4.928 billion.
What are the leading health concept stocks
1, Dean Diagnostics (28.30 +1.25%, diagnostic shares): the layout of high-end precision diagnostic technology platform, cooperation *** build business growth is rapid, has been in a number of tertiary hospitals customers extend *** build precision platform.
2, the United States and Hong Kong Biological (23.45 +0.04%, diagnostic shares): has obtained 145 in vitro diagnostic reagents product registration certificates, covering biochemical, blood cells and other fields.
3, Jiuzhou Tong (20.04 +0.50%, diagnosis): its wholly owned subsidiary of the good pharmacist pharmacy and Kang Sheng medicine signed a strategic cooperation framework agreement, plans to gradually realize the Kang Yuan series of medicines within three years, the health food series for cooperation.
4, Lucking health (6.26-1.11%, diagnosis): the company is one of the earlier engaged in the development and production of home sauna equipment, is to promote the health of the sauna into the domestic ordinary family pioneers. The main products mainly include home far-infrared sauna room and portable sauna products two categories.
5, Beida medicine (000788): the acquisition of Beida medicine to complete the business expansion. The company in 2011 to the Beida international hospital group directional hair acquisition to buy 100% of the equity of Beida medicine. North medicine medicine and its subsidiaries from 2011 into the company statement. The company added into the drug, medical equipment sales and distribution business, the pharmaceutical industry chain is further extended.